Bicara enables access to the thriving innovation ecosystem which accelerates our development of therapies for cancer. Synergies between the Bicara teams in Boston and Bengaluru will pioneer breakthrough innovation.
Location: United States, Massachusetts, Cambridge
Total raised: $635M
Investors 7
| Date | Name | Website |
| 24.02.2024 | Aisling Ca... | aislingcap... |
| 04.04.2023 | Omega Fund... | omegafunds... |
| - | F-Prime Ca... | fprimecapi... |
| 05.04.2022 | Cavendish ... | cavendishf... |
| 03.11.2022 | Red Tree V... | redtreevc.... |
| - | Bioqube Ve... | bioqubeven... |
| - | Eight Road... | eightroads... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 21.09.2024 | IPO | $362M | - |
| 10.01.2024 | Series C | $165M | - |
| 24.03.2023 | Series B | $108M | Janus Hend... |
Mentions in press and media 21
| Date | Title | Description |
| 21.09.2024 | Bicara Therapeutics Soars with $362 Million IPO: A New Dawn for Cancer Treatment | Bicara Therapeutics Inc. has made a significant splash in the biopharmaceutical pool. The company recently closed its initial public offering (IPO), raising a staggering $362 million. This move marks a pivotal moment for a firm dedicated to... |
| 21.09.2024 | Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the cl... |
| 16.09.2024 | Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the c... |
| 07.09.2024 | Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development | BOSTON, Mass., March 26, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointments of Jeltje Schulten, M.D., MBA, as ... |
| 07.09.2024 | Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | First-in-class bifunctional EGFR/TGF-β inhibitor, ficerafusp alfa, in combination with pembrolizumab has demonstrated clinically meaningful anti-tumor activity and significant improvement over standard of care in HNSCC with at least 12 mont... |
| 07.09.2024 | Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. | BOSTON, Mass., August 15, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the appointments of Mike Powell, Ph.D., and Christ... |
| 10.01.2024 | Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing | Proceeds to accelerate clinical development of first-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, for multiple cancer types, including 1L HPV-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) |
| 20.12.2023 | Bicara Therapeutics: Clinical-Stage Biotechnology Company Raises Oversubscribed $165 Million Funding Round | Bicara Therapeutics – a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response – recently announced the completion of an oversubscribed $165 million Series C financing. The fundi... |
| 13.12.2023 | Bicara Therapeutics Raises $165M in Series C Financing | Bicara Therapeutics, a Boston, MA-based clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, closed a $165m Series C financing. The round was co-led by Braidwell LP and TPG, w... |
| 12.12.2023 | Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing | - |
Show more